Sugi Predict

Sugi Predict / Compounds / SCHEMBL13065950

SCHEMBL13065950

SCHEMBL13065950

CC(=O)c1cccc(-c2ccccc2)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDCD1 Q15116 5/20 0.52
▸ CD274 Q9NZQ7 5/20 0.52
▸ HNF4A P41235 1/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ BCAT2 O15382 1/20 0.50
▸ CHRNB2 P17787 1/20 0.49
▸ CHRNB4 P30926 1/20 0.49
▸ CHRNA3 P32297 1/20 0.49
▸ CHRNA4 P43681 1/20 0.49
▸ MYC P01106 1/20 0.46
▸ MAPT P10636 1/20 0.44
▸ GAA P10253 2/20 0.43
▸ FABP3 P05413 1/20 0.43
▸ FABP4 P15090 1/20 0.43
▸ FABP5 Q01469 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ HSP90AB1 P08238 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121422 0.86 HNF4A (0.63) PDCD1CD274HNF4ASMN1; SMN2L3MBTL1
SCHEMBL25550174 0.86 MYC (0.44) SMN1; SMN2L3MBTL1MYCLMNAKDM4E
SCHEMBL28870199 0.85 SMN1; SMN2 (0.46) PDCD1CD274HNF4ASMN1; SMN2L3MBTL1
SCHEMBL10568634 0.84 PDCD1 (0.55) PDCD1CD274HNF4ASMN1; SMN2L3MBTL1
SCHEMBL1395221 0.84 ALDH1A1 (0.46) L3MBTL1HTTALDH1A1
SCHEMBL30955031 0.84 BCAT2 (0.57) HNF4ASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL294730 0.84 BCAT2 (0.63) HNF4ASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL31125227 0.84 BCAT2 (0.63) HNF4ASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL30034930 0.83 BCAT2 (0.69) PDCD1CD274HNF4ASMN1; SMN2L3MBTL1
SCHEMBL530285 0.83 BCAT2 (0.69) PDCD1CD274HNF4ASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116041277-B Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-11-01 — — CN disclosed
CN-118026947-A Biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-05-14 — — CN disclosed
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-06-22 — — US disclosed
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-06-22 — — US disclosed
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-06-22 — — US disclosed
CN-116041277-A Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof 中国药科大学 2023-05-02 — — CN disclosed
US-11608337-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-03-21 — — US disclosed
EP-3365340-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2022-08-10 — — EP disclosed
US-11407749-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2022-08-09 — — US disclosed
EP-3452476-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2021-12-15 — — EP disclosed
WO-2017192961-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-11-09 — — WO disclosed
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-11-09 — — US disclosed
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-11-09 — — US disclosed
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-11-09 — — US disclosed
WO-2017070089-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-04-27 — — WO disclosed
WO-2017070089-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-04-27 — — WO disclosed
US-20170107216-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-04-20 — — US disclosed
US-20170107216-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-04-20 — — US disclosed
US-20170107216-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-04-20 — — US disclosed
WO-2010131922-A2 AMIDE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885HNF4A 1997/4885
US-11407749-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS PDCD1 201/4885CD274 97/4885HNF4A 2095/4885
US-20170107216-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PDCD1 201/4885CD274 97/4885HNF4A 2095/4885
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885HNF4A 1997/4885
US-11608337-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885HNF4A 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.